Search Login Register
Glycogen Storage Disease Type IIb
Summary
23
relevant articles (0 outcomes,
1 trials/studies)
found for this Disease
Description:
An X-linked dominant multisystem disorder resulting in cardiomyopathy, myopathy and MENTAL RETARDATION. It is caused by mutation in the gene encoding LYSOSOMAL-ASSOCIATED MEMBRANE PROTEIN 2.
Also Known As:
Danon Disease; Glycogen Storage Disease IIb; Vacuolar Cardiomyopathy and Myopathy, X-linked; X-Linked Vacuolar Cardiomyopathy and Myopathy; Disease, Danon Show All >>
Key Drugs and Agents for Glycogen Storage Disease Type IIb
Efficacy Chart >>
Drugs and Important Biological Agents (IBA) related to treatments:
-
alpha-Glucosidases (Acid Maltase)
:
10 results
: IBA
-
Lysosomal-Associated Membrane Protein 2
:
3 results
: IBA
-
Membrane Proteins (Integral Membrane Proteins)
:
3 results
: IBA
-
Triad
:
2 results
:
FDA 1
-
RNA Splice Sites
:
1 result
: IBA
-
Retinaldehyde (Retinal)
:
1 result
: IBA
-
Membrane Glycoproteins (Membrane Glycoprotein)
:
1 result
: IBA
-
Glycogen
:
1 result
: IBA
-
DNA (Deoxyribonucleic Acid)
:
1 result
: IBA
-
lysosomal proteins
:
1 result
: IBA
Diseases Related to Glycogen Storage Disease Type IIb
-
Muscular Diseases (Myopathy)
-
Glycogen Storage Disease (Glycogenosis)
-
Mental Retardation (Idiocy)
-
Cardiomyopathies (Cardiomyopathy)
-
Hypertrophic Cardiomyopathy (Asymmetric Septal Hypertrophy)
Show All >>
Key Therapies for Glycogen Storage Disease Type IIb
Efficacy Chart >>
-
Heart Transplantation (Grafting, Heart)
:
1 study in 4 results
CureHunter Inc. provides medical information and specifically does NOT provide medical advice.
© Copyright 2003-2008 CureHunter Inc., MeSH copyright NLM, Journal Articles copyright original owners.